Jim Simons’s Revolution Medicines RVMD Stock Holding History

Jim Simons’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,200	Closed	-$603K	–	3559
2026 Q1	$603K	Buy	+6,200	New	+$626K	﹤0.01%	2522
2025 Q4	–	Sell	-253,104	Closed	-$11.8M	–	3681
2025 Q3	$11.8M	Buy	253,104 +9,600	+4%	+$376K	0.02%	1008
2025 Q2	$8.96M	Buy	243,504 +100,700	+71%	+$3.87M	0.01%	1127
2025 Q1	$5.05M	Buy	+142,804	New	+$5.8M	0.01%	1426
2023 Q2	–	Sell	-43,300	Closed	-$938K	–	4218
2023 Q1	$938K	Buy	+43,300	New	+$1.07M	﹤0.01%	2521
2022 Q4	–	Sell	-68,900	Closed	-$1.36M	–	4357
2022 Q3	$1.36M	Buy	+68,900	New	+$1.51M	﹤0.01%	2297
2022 Q1	–	Sell	-55,100	Closed	-$1.39M	–	4403
2021 Q4	$1.39M	Buy	+55,100	New	+$1.55M	﹤0.01%	2425
2021 Q3	–	Sell	-22,900	Closed	-$727K	–	3787
2021 Q2	$727K	Buy	22,900 +13,300	+139%	+$464K	﹤0.01%	2806
2021 Q1	$440K	Buy	+9,600	New	+$430K	﹤0.01%	2954

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jim Simons's RVMD Position: Q2 2026 in Review

Jim Simons sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 6,200 shares — an estimated $603K sold.

Jim Simons first reported a position in RVMD in Q1 2021 and held it in 9 quarters. The position peaked at $11.8M in Q3 2025. 696 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Jim Simons reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
Jim Simons sold 6,200 Revolution Medicines shares in Q2 2026, an estimated $603K.
Jim Simons first reported a position in Revolution Medicines in Q1 2021 and held it in 9 quarters.
Jim Simons's Revolution Medicines position peaked at $11.8M in Q3 2025.
696 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.